A protein in glioma may make treatment harder to work
Original title: Targeting the Metabolic-Immune Regulator SLC35F6 Enhances Temozolomide and Anti-PD-L1 Therapy in Glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was done in cells and animals only, not in people.
The short version
Turning down one protein helped two glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary drugs work better in lab and animal tests.
What was studied. Researchers studied public databases and 179 samples from people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They looked at a protein called SLC35F6 and what happened when they turned it down.
What they found. SLC35F6 levels were high in glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, and high levels went with worse outcomes. Turning it down changed how the tumor cells made energy from sugar. It also changed nearby immune cells, so the tumors responded better to the chemo drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary and to an anti-PD-L1 drug.
What this means, and what it doesn't
What it could mean: This gives scientists a new target to aim at in glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. It may help explain why some tumors resist temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. It does not change any treatment you can get now.
What it doesn't mean: This is early work in cells and animals, not care a patient can receive. No person with a brain tumor was treated this way here. It is not a cure, and it is not proof it will help people. Safety tests in people would have to come first, and that takes years.
Source: PubMed, October 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.